Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Takimoto

Showing results (1-10 of 229) with videos related to

Pageof 23
Sort By:
Cancer Chemotherapy and Pharmacology|June 24, 2003
Anticancer drug development at the US National Cancer InstituteChris H Takimoto
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug developmentChris H Takimoto
Current Problems in Cancer|June 16, 2001
The clinical pharmacology of the oral fluoropyrimidinesC H Takimoto
European Journal of Cancer (Oxford, England : 1990)|January 28, 2006
Chronomodulated chemotherapy for colorectal cancer: failing the test of time?Chris H Takimoto
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Are there any better camptothecins than the ones we have?Chris H Takimoto
Nature Clinical Practice. Oncology|November 3, 2005
Can docetaxel dosing be individualized based on cytochrome p450 activity?Chris H Takimoto
Cancer Chemotherapy and Pharmacology|July 11, 2008
Phase 0 clinical trials in oncology: a paradigm shift for early drug development?Chris H Takimoto
Seminars in Oncology|January 7, 1998
Antifolates in clinical developmentC H Takimoto
Nature Clinical Practice. Oncology|January 25, 2007
Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?Chris H Takimoto
Targeted Oncology|April 21, 2009
Maximum tolerated dose: clinical endpoint for a bygone era?Chris H Takimoto
Pageof 23

Showing results (1-10 of 229) with videos related to

Sort By:
Pageof 23
Cancer Chemotherapy and Pharmacology|June 24, 2003
Anticancer drug development at the US National Cancer InstituteChris H Takimoto
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug developmentChris H Takimoto
Current Problems in Cancer|June 16, 2001
The clinical pharmacology of the oral fluoropyrimidinesC H Takimoto
European Journal of Cancer (Oxford, England : 1990)|January 28, 2006
Chronomodulated chemotherapy for colorectal cancer: failing the test of time?Chris H Takimoto
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Are there any better camptothecins than the ones we have?Chris H Takimoto
Nature Clinical Practice. Oncology|November 3, 2005
Can docetaxel dosing be individualized based on cytochrome p450 activity?Chris H Takimoto
Cancer Chemotherapy and Pharmacology|July 11, 2008
Phase 0 clinical trials in oncology: a paradigm shift for early drug development?Chris H Takimoto
Seminars in Oncology|January 7, 1998
Antifolates in clinical developmentC H Takimoto
Nature Clinical Practice. Oncology|January 25, 2007
Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?Chris H Takimoto
Targeted Oncology|April 21, 2009
Maximum tolerated dose: clinical endpoint for a bygone era?Chris H Takimoto
Pageof 23